Publications
Found 2 results
Filters: Author is K.H. Alzoubi [Clear All Filters]
“Assessment of genotoxicity of waterpipe smoking using 8-OHdG biomarker”, vol. 14, pp. 9555-9561, 2015.
, “Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant”, vol. 12, pp. 801-808, 2013.
, Cascorbi I (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb. Exp. Pharmacol. 201: 261-283.
http://dx.doi.org/10.1007/978-3-642-14541-4_6
PMid:21103972
Chelule PK, Gordon M, Palanee T, Page T, et al. (2003). MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin. Pharmacol. Ther. 74: 195-196.
http://dx.doi.org/10.1016/S0009-9236(03)00151-6
Chen J, Chen L, Mao N and Liu Y (2011). Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol. Int. 32: 3127-3130.
http://dx.doi.org/10.1007/s00296-011-2088-3
PMid:21947347
D'Andrea G, D'Ambrosio R and Margaglione M (2008). Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. Blood Rev. 22: 127-140.
PMid:18234403
Fojo A, Lebo R, Shimizu N, Chin JE, et al. (1986). Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat. Cell Mol. Genet. 12: 415-420.
http://dx.doi.org/10.1007/BF01570737
PMid:3016920
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, et al. (2003). Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 59: 303-312.
http://dx.doi.org/10.1007/s00228-003-0606-2
PMid:12879168
Gumus-Akay G, Rustemoglu A, Karadag A and Sunguroglu A (2008). Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population. Genet. Mol. Res. 7: 1193-1199.
http://dx.doi.org/10.4238/vol7-4gmr496
PMid:19048498
Hattori H, Suminoe A, Wada M, Koga Y, et al. (2007). Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk. Res. 31: 1633-1640.
http://dx.doi.org/10.1016/j.leukres.2007.04.009
PMid:17568669
Hawkins GA and Peters SP (2008). Pharmacogenetics of asthma. Methods Mol. Biol. 448: 359-378.
http://dx.doi.org/10.1007/978-1-59745-205-2_11
PMid:18370237
He T, Mo A, Zhang K and Liu L (2011). ABCB1/MDR1 polymorphism and colorectal cancer risk: a meta-analysis of case-control studies. Colorectal Dis. [Epub ahead of print].
http://dx.doi.org/10.1111/j.1463-1318.2011.02919.x
Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, et al. (1997). Structure of the multidrug resistance P-glycoprotein. Semin. Cancer Biol. 8: 135-142.
http://dx.doi.org/10.1006/scbi.1997.0067
PMid:9441943
Huebner C, Browning BL, Petermann I, Han DY, et al. (2009). Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm. Bowel. Dis. 15: 1784-1793.
http://dx.doi.org/10.1002/ibd.21019
PMid:19685447
Kadiev E, Patel V, Rad P, Thankachan L, et al. (2008). Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert. Opin. Drug Metab. Toxicol. 4: 77-91.
http://dx.doi.org/10.1517/17425255.4.1.77
PMid:18370860
Kasuya K, Tsuchida A, Nagakawa Y, Suzuki Y, et al. (2012). Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. Hepatogastroenterology 59: 1609-1613.
PMid:22155850
Katz DA and Bhathena A (2009). Overview of pharmacogenetics. Curr. Protoc. Hum. Genet. Chapter 9: Unit.
Khabour OF, Abdelhalim ES and Abu-Wardeh A (2009). Association between SOD2 T-9C and MTHFR C677T polymorphisms and longevity: a study in Jordanian population. BMC Geriatr. 9: 57.
http://dx.doi.org/10.1186/1471-2318-9-57
PMid:20003469 PMCid:2801492
Kim RB, Leake BF, Choo EF, Dresser GK, et al. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70: 189-199.
http://dx.doi.org/10.1067/mcp.2001.117412
PMid:11503014
Komoto C, Nakamura T, Sakaeda T, Kroetz DL, et al. (2006). MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab. Pharmacokinet. 21: 126-132.
http://dx.doi.org/10.2133/dmpk.21.126
PMid:16702732
Kuypers DR, de Jonge H, Naesens M and Vanrenterghem Y (2008). Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics 18: 861-868.
http://dx.doi.org/10.1097/FPC.0b013e328307c26e
PMid:18704002
Lewis DR, Miller ND, Splitt BL, Wu G, et al. (2007). Separating the roles of acropetal and basipetal auxin transport on gravitropism with mutations in two Arabidopsis multidrug resistance-like ABC transporter genes. Plant Cell 19: 1838-1850.
http://dx.doi.org/10.1105/tpc.107.051599
PMid:17557805 PMCid:1955737
Li Y, Yan PW, Huang XE and Li CG (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac. J. Cancer Prev. 12: 2405-2409.
PMid:22296392
Li Y, Hu X, Cai B, Chen J, et al. (2012). Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl. Immunol. 27: 12-18.
http://dx.doi.org/10.1016/j.trim.2012.03.006
PMid:22504573
Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, et al. (2011). Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma. J. Exp. Clin. Cancer Res. 30: 68.
http://dx.doi.org/10.1186/1756-9966-30-68
PMid:21762523 PMCid:3154152
Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, et al. (2011). Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol. Rep. 63: 808-814.
PMid:21857092
Ni LN, Li JY, Miao KR, Qiao C, et al. (2011). Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol. 28: 265-269.
http://dx.doi.org/10.1007/s12032-010-9456-9
PMid:20204543
Pan JH, Han JX, Wu JM, Huang HN, et al. (2009). MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78: 49-55.
http://dx.doi.org/10.1159/000158454
PMid:18812689
Ponnala S, Chaudhari JR, Jaleel MA, Bhiladvala D, et al. (2012). Role of MDR1 C3435T and GABRG2 C588T gene polymorphisms in seizure occurrence and MDR1 effect on anti-epileptic drug (phenytoin) absorption. Genet. Test. Mol. Biomarkers 16: 550-557.
http://dx.doi.org/10.1089/gtmb.2011.0225
PMid:22239287
Potocnik U, Glavac D and Dean M (2008). Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet. Cytogenet. 183: 28-34.
http://dx.doi.org/10.1016/j.cancergencyto.2008.01.023
PMid:18474294
Qian X, Cao S, Yang G, Dong J, et al. (2012). Variant genotypes of MDR1 C3435T increase the risk of leukemia: evidence from 10 case-control studies. Leuk. Lymphoma 53: 1183-1187.
http://dx.doi.org/10.3109/10428194.2011.641179
PMid:22088099
Roses AD (2008). Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 7: 807-817.
http://dx.doi.org/10.1038/nrd2593
PMid:18806753
Sipeky C, Csongei V, Jaromi L, Safrany E, et al. (2011). Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug Metab. Pharmacokinet. 26: 206-215.
http://dx.doi.org/10.2133/dmpk.DMPK-10-SC-068
PMid:21178299
Turgut S, Turgut G and Atalay EO (2006). Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. Mol. Biol. Rep. 33: 295-300.
http://dx.doi.org/10.1007/s11033-006-9022-x
PMid:17080296
van Schaik RH (2008). CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist. Updat. 11: 77-98.
http://dx.doi.org/10.1016/j.drup.2008.03.002
PMid:18486526
Vella A and Camilleri M (2008). Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert. Opin. Pharmacother. 9: 1109-1119.
http://dx.doi.org/10.1517/14656566.9.7.1109
PMid:18422469
Wang Y, Wang C, Li J, Wang X, et al. (2009). Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur. J. Clin. Pharmacol. 65: 239-247.
http://dx.doi.org/10.1007/s00228-008-0577-4
PMid:18936931
Wang Y, Chen Q, Jin S, Deng W, et al. (2012). Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Scand. J. Gastroenterol. 47: 802-808.
http://dx.doi.org/10.3109/00365521.2012.683042
PMid:22545578
Yan PW, Huang XE, Yan F, Xu L, et al. (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac. J. Cancer Prev. 12: 2291-2294.
PMid:22296372
Yu X, Xie H, Wei B, Zhang M, et al. (2011). Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One 6: e25933.
http://dx.doi.org/10.1371/journal.pone.0025933
PMid:22110582 PMCid:3215699
Zhang Y, Jiang XH, Hu YQ, Li ZR, et al. (2008). MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br. J. Clin. Pharmacol. 66: 247-254.
http://dx.doi.org/10.1111/j.1365-2125.2008.03189.x
PMid:18460034 PMCid:2492918